Gemtuzumab Ozogamicin Approved in Europe for CD33+ AML

April 25, 2018 – The European Commission has approved the antibody-drug conjugate gemtuzumab ozogamicin for use in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and older with newly diagnosed, CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia. Up to 90% of patients with AML have CD33 expression on their AML cells, according to Pfizer, the manufacturer of gemtuzumab ozogamicin … (leggi tutto)